SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD — Progress Note 5 — Focused Visit (Follow-up) — Irène Joliot-Curie — True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.

PatientIrène Joliot-Curie
Date of birth1897-09-12
IdentifiersMRN HR-RB003-SYN-TD; SSN (made up) 000-03-8841
Document date1955-10-19
AuthorSolène Marchand-Ellis, MD
CustodianSt. Posthumous Health Center

Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.

Chief Complaint

Day 22 of cycle 1: bone marrow response and count recovery. [S]

History of Present Illness

Mrs. Joliot-Curie returns on day 22 of her first cycle. She spent five days in hospital for the ramp-up without tumor lysis. The nausea and constipation of the second week settled within three days on ondansetron and laxatives, and she has needed no ondansetron for a week. She has had no fever. She had one more unit of red cells and one dose of platelets on day 11 and none since. She had her bone marrow biopsy this morning. She has met the palliative care team again and the transplant center once. Her dose records have not yet arrived. [S]

ElementDetail
CycleDay 22 of cycle 1 of azacitidine with venetoclax 70 mg daily
Side effectsNausea and constipation settled; no fever or infection
TransfusionsOne unit of red cells and one dose of platelets on day 11

Review of Systems

SystemResultFinding
ConstitutionalPositiveTired; no fever or chills
Ears, nose, mouth, and throatNegativeNo mouth sores or sore throat
RespiratoryNegativeNo cough; breathless on stairs as before
GastrointestinalNegativeNo nausea, diarrhea or constipation now
IntegumentaryNegativeNo new bruises or rash

5 systems reviewed. [S]

Medications

MedicationFrequencyRouteDatesStatusEvidence
Azacitidine 115 mg (75 mg/m2) under the skin once daily on days 1 to 7 of each 28-day cycleOnce daily on days 1 to 7 of each 28-day cycleSubcutaneous route1955-09-28activeS
Venetoclax 10 mg oral tablet, cycle 1: 10 mg on day 1 and 20 mg on day 2, then two tablets (20 mg) daily with the 50 mg tablet from day 4 (70 mg a day, reduced for posaconazole)Ramp-up, then two tablets daily with the 50 mg tablet, with food and waterOral route1955-09-28 to 1955-10-19completedS
Venetoclax 50 mg oral tablet, cycle 1: one tablet alone on day 3 (50 mg), then one tablet daily with two 10 mg tablets from day 4 (70 mg a day)One tablet daily from day 3, with food and waterOral route1955-09-28 to 1955-10-19completedS
Posaconazole 100 mg delayed-release tablet, three tablets (300 mg) twice on day 1, then three tablets once daily, as antifungal prophylaxis while neutropenic300 mg twice on day 1, then 300 mg once daily with foodOral route1955-09-28activeS
Acyclovir 400 mg oral tablet, one tablet twice daily as herpes simplex and zoster prophylaxisOne tablet twice dailyOral route1955-09-28activeS
Levofloxacin 500 mg oral tablet, one tablet daily while the neutrophil count is below 0.5One tablet daily during profound neutropeniaOral route1955-09-28 to 1955-10-30completedS
Allopurinol 300 mg oral tablet, one tablet daily for tumor lysis prophylaxis during cycle 1One tablet dailyOral route1955-09-28 to 1955-10-19completedS
Ondansetron 4 mg orally disintegrating tablet, one tablet every 8 hours as needed for nauseaOne tablet every 8 hours as neededOral route1955-10-08activeS
Polyethylene glycol 3350, 17 g powder in a glass of water once daily17 g once daily, held for loose stoolsOral route1955-10-08activeS
Sennosides 8.6 mg oral tablet, two tablets at bedtimeTwo tablets at bedtimeOral route1955-10-08 to 1955-10-19completedS
Potassium chloride 20 mEq extended-release tablet, one tablet twice daily for three daysOne tablet twice daily for three daysOral route1955-10-08 to 1955-10-11completedS

Allergies and Intolerances

AllergyReactionStatusEvidence
No known allergyactiveS

Vital Signs

DateMeasureValueUnitProvenance
1955-10-19Body height163cmS
1955-10-19Body weight52.8kgS
1955-10-19Body mass index (BMI) [Ratio]19.9kg/m2S
1955-10-19Systolic blood pressure110mm[Hg]S
1955-10-19Diastolic blood pressure66mm[Hg]S
1955-10-19Heart rate90/minS
1955-10-19Respiratory rate16/minS
1955-10-19Body temperature37CelS
1955-10-19Oxygen saturation in Arterial blood by Pulse oximetry97%S

Results

DateMeasureValueUnitReference rangeFlagProvenance
1955-10-19Leukocytes [#/volume] in Blood by Automated count0.610*3/uL4-11 10*3/uLLowS
1955-10-19Neutrophils [#/volume] in Blood by Automated count0.210*3/uL1.5-7.5 10*3/uLLowS
1955-10-19Hemoglobin [Mass/volume] in Blood8.9g/dL12-15.5 g/dLLowS
1955-10-19Platelets [#/volume] in Blood by Automated count3110*3/uL150-400 10*3/uLLowS
1955-10-19Blasts/Leukocytes in Blood by Manual count0%None seen normallyNormalS
1955-10-19Blasts/cells in Bone marrow3%Below 5% normally; 20% or more defines AMLNormalS
1955-10-19Sodium [Moles/volume] in Serum or Plasma138mmol/L135-145 mmol/LNormalS
1955-10-19Potassium [Moles/volume] in Serum or Plasma3.9mmol/L3.5-5.1 mmol/LNormalS
1955-10-19Creatinine [Mass/volume] in Serum or Plasma0.79mg/dL0.57-1 mg/dLNormalS
1955-10-19Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 1950)/1.73 sq M87mL/min/{1.73_m2}>=60 mL/min/1.73 m²NormalS
1955-10-19Lactate dehydrogenase [Enzymatic activity/volume] in Serum or Plasma196U/L140-280 U/LNormalS
1955-10-19Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma31U/L7-35 U/LNormalS

Physical Exam

Vital signs recorded on 1955-10-19; see the Vital Signs section. [S]

SystemFinding
GeneralTired but well; weight 52.8 kg; temperature 37.0 °C
MouthNo ulcers or thrush
RespiratoryFine crackles at the right apex, unchanged
SkinInjection sites healed; no rash
AbdomenSoft, non-tender

Problems

ProblemClinical statusVerificationCodeProvenance
Two months of tiredness, easy bruising and bleeding gums, with pancytopenia and 12 percent blasts on the blood smear; acute leukemia suspected and urgent hematology review bookedresolvedconfirmed D61.818S — Synthetic presenting concern at the index visit, superseded by the bone marrow diagnosis two days later; its timing echoes the documented decline in her health (D).
Acute myeloid leukemia diagnosed on bone marrow biopsy (34 percent myeloblasts), in a physicist with decades of occupational exposure to ionizing radiation; synthetic modern diagnosis linked to her documented leukemiaactiveconfirmed C92.00S — Synthetic modern diagnosis and subtype; the type of her real leukemia is not documented.
Occupational exposure to ionizing radiation over about four decades: X-ray work early in her career, laboratory work with polonium and other radioactive sources, and a laboratory accident in which a sealed polonium source ruptured on her bench about ten years agoactiveconfirmed Z57.1S — Synthetic modern coding of her documented occupational exposure.
Pulmonary tuberculosis in her forties, treated to completion; no symptoms of active diseaseactiveconfirmed Z86.11S — Synthetic modern coding of her documented tuberculosis; the treatment details are synthetic.
Moderately reduced lung gas transfer (DLCO 58 percent of predicted, FEV1 76 percent) from old tuberculous scarring of the right upper lobe; with performance status 2, it makes her unfit for intensive inductionactiveconfirmed R94.2S — Synthetic finding on pre-treatment testing.
Nausea with vomiting and constipation on day 11 of cycle 1 of azacitidine with venetoclax, without fever, with mild low potassium; managed as an outpatient; resolvedresolvedconfirmed R11.2S — Synthetic treatment side effect; not a historical claim.

Assessment and Plan

Protocol monitoring: items the monitoring protocol calls for at this visit. [S]

DomainMeasureIntervalStatusDetail
LaboratoryBlood count with differential and smearAt diagnosis; two to three times a week during induction; before each cycleCompleted todayWhite cells 0.6, neutrophils 0.2, hemoglobin 8.9 g/dL, platelets 31 x10^3/uL; no blasts on the smear
LaboratoryBone marrow: morphology, flow cytometry, cytogenetics, molecular panelAt diagnosis; day 21 to 28 of cycle 1; then as response and transplant planning requireCompleted todayDay-22 marrow: about 10% cellular, 3% blasts; flow MRD 0.6%: leukemia-free marrow; venetoclax stopped for count recovery
LaboratoryChemistry: electrolytes, creatinine, calcium, phosphate, uric acid, LDH, liver testsAt diagnosis; during venetoclax ramp-up for tumor lysis; then weekly in cycle 1 and before each cycleCompleted todaySodium 138, potassium 3.9 mmol/L; creatinine 0.79 mg/dL, eGFR 87; LDH 196 U/L; ALT 31 U/L
Medication safetyAzole safety: posaconazole interactions (venetoclax dose), liver tests, QTc, trough levelAt start; liver tests weekly; trough level after about a week of dosing; QTc with any added QT-prolonging drugDeferredMissed: the posaconazole trough level due after about a week of dosing was not drawn. No harm judging by the absence of fever or fungal infection, normal liver tests, and a QTc of 446 ms on day 11. Corrective action: trough level with the next blood count, and added to the cycle order set
Medication safetyTransfusion support: thresholds, irradiated and leukoreduced productsAt each blood countCompleted todayNo transfusion needed today
Self-managementInfection prophylaxis and the fever planThroughout neutropeniaCompleted todayNo fever; prophylaxis taken as prescribed; fever plan reviewed
ReferralHLA typing and allogeneic transplant evaluationDuring cycle 1Completed todaySeen once at the transplant center; unrelated donor search under way
ReferralSpecialist palliative care: symptoms, prognosis, goals and valuesAt every visitCompleted todaySecond palliative care visit last week; symptoms controlled
Self-managementOccupational exposure history and dose recordsUntil the records are receivedDueRecords not yet received; second request sent

Goal progress:

Guideline basis: NCCN Clinical Practice Guidelines in Oncology: Acute Myeloid Leukemia, Version 5.2026 (2026); Döhner H, et al. Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood 2022 (PMID 35797463) (2022); DiNardo CD, et al. Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia (VIALE-A). N Engl J Med 2020 (PMID 32786187) (2020); NCCN Clinical Practice Guidelines in Oncology: Prevention and Treatment of Cancer-Related Infections (2026); Taplitz RA, et al. Outpatient Management of Fever and Neutropenia in Adults Treated for Malignancy: ASCO and IDSA Clinical Practice Guideline Update (PMID 29461916) (2018); Sanders JJ, et al. Palliative Care for Patients With Cancer: ASCO Guideline Update. J Clin Oncol 2024 (PMID 38748941) (2024); Carson JL, et al. Red Blood Cell Transfusion: 2023 AABB International Guidelines. JAMA 2023 (PMID 37824153) (2023); Kaufman RM, et al. Platelet transfusion: a clinical practice guideline from the AABB. Ann Intern Med 2015 (PMID 25383671) (2015); 10 CFR 19.13, Notifications and reports to individuals (radiation exposure reports on request) (2026); 29 CFR 1910.1096, Ionizing radiation (records of exposure and disclosure to employees) (2026)

Follow-up: Blood count twice weekly with the posaconazole level. Response review and the cycle 2 decision when counts recover. Emergency department at once for a temperature of 38.0 °C or more. Next scheduled visit 1955-10-26: periodic adult preventive visit during AML therapy. [S]